LOS ANGELES, CA - 03/07/2019 (PRDistribution.com)
MyoStim ED, a biotechnology company focused on bioelectric and biologics treatment of erectile dysfunction, today announced that a team led by C. Carboni, MSc will present data from a randomized controlled clinical study on March 9th, 2019 at 6pm at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Atlanta at the Grand Hyatt Atlanta - link to poster https://www.statusplus.net/isswsh/atlanta2019/posters/view.php?pid=91. + link to abstract http://www.isswshmeeting.org/2019/program
The team will also present the design of a new Phase IIb clinical study, which is enrolling now, which includes additional bioelectric signaling sequences and more comprehensive followup. The new study includes bioelectric signals in sequences intended to recruit stem cells, to mature blood vessels, regenerate muscle and repair nerve damage. The first study, independently conducted in Brazil, focused primarily on electrical stimulation to grow small micro blood vessels.
The initial study https://www.ncbi.nlm.nih.gov/pubmed/29785045 yielded these results:
- 3/11 patients regained full spontaneous erections
- 5/11 patients improve statistically significant in the IIEF-5 score 3/11 were FES failures
- Control group no spontaneous improvement in erectile function was observed based in the IIEF-5 score.
"We achieved satisfactory results with our first small scale randomized controlled study with just a single bioelectric signaling sequence applied only 15 minutes 2X a week for 4 weeks. The new study will have 5 additional bioelectric signaling sequences and the treatment time will be more than double that of the previous study and the followup of each patient will be more comprehensive. We look forward to reporting later this year or early next year the results from this new study." Cristiane Carboni, MSc Lead Investigator, Department of Health Science and Rehabilitation, Federal University of Health Sciences of Porto Alegre-UFCSPA, Porto Alegre, Rio Grande do Sul, Brazil.
About MyoStim ED: MyoStim ED www.erectistim.com is a startup focused on bioelectric and biologics erectile dysfunction treatment within the Leonhardt's Launchpads innovation and startup accelerator with lab and R&D locations in Los Angeles, Petaluma, Salt Lake City and Pittsburgh. For Frequently Asked Questions answers click here > https://erectistim.com/faq/
Leonhardt's Launchpads: Leonhardt's Launchpads www.leonhardtventures.com is the innovation and startup accelerator arm of Leonhardt Ventures focused on bioelectric and biologics organ regeneration and recovery technologies. 30 startups are in the 2019 portfolio class. The accelerator business model is to accelerate each organ specific innovation and corresponding startup through first-in-man results and then seek out a strategic buyer/partner to complete the pathway to commercialization.
Forward-Looking Statements and Disclaimers: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Risk Factors" and other sections of our most recent Annual Report or Private Placement Memorandum.Any investment in MyoStim ED or our accelerator has to be regarded in the highest risk category for total loss due to the early stage nature of the developments. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. The company may not maintain any patent licenses mentioned and any patents pending mentioned may not be issued. The company lacks sufficient resources to bring these products to market. Technologies mentioned are NOT yet proven to be safe or effective in statistically significant properly controlled studies.
SOURCE Leonhardt's Launchpads
Leonhardt's Launchpads by Cal-X Stars, 12655 W Jefferson Blvd, Los Angeles, CA 90066
Leonhardt's Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115
Leonhardt’s Launchpads Pittsburgh, 2730 Sidney Street, Suite 300, Pittsburgh, PA 15203
Google VoiceMail for all Offices: (424) 291-2133